首页 / 院系成果 / 成果详情页

Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data 期刊论文

编号：

d1bc732c-c814-476b-a4fe-06b4174bb567
作者：

Qi, WeiXiang#^[1]Wang, Qiong#^[1]Jiang, YanLing^[2];Sun, YuanJue^[1];Tang, Lina^[1];He, Aina^[1];Min, Daliu^[1];Lin, Feng^[1];Shen, Zan*^[1]Yao, Yang*^[1]
语种：

英文
期刊：

PLOS ONE ISSN：1932-6203 2013 年 8 卷 2 期 ; FEB 8
收录：
摘要：

Background: Combining targeted therapy has been extensively investigated in previously treated advanced non-small-cell lung cancer (NSCLC), but it is still unclear whether combining targeted therapy might offer any benefits against standard monotherapy with erlotinib. We thus performed a meta-analysis of randomized controlled trials to compare the efficacy and safety of combining targeted therapy versus erlotinib alone as second-line treatment for advanced NSCLC.
Methods: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and grade 3 or 4 adverse event (AEs). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.
Results: Eight eligible trials involved 2417 patients were ultimately identified. The intention to treatment (ITT) analysis demonstrated that combining targeted therapy significantly improved OS (HR 0.90, 95% CI: 0.82-0.99, p = 0.024), PFS (HR 0.83, 95% CI: 0.72-0.97, p = 0.018), and ORR (OR 1.35, 95% CI 1.01-1.80, P = 0.04). Sub-group analysis based on phases of trials, EGFR-status and KRAS status also showed that there was a tendency to improve PFS and OS in combining targeted therapy, except that PFS for patients with EGFR-mutation or wild type KRAS favored erlotinib monotherapy. Additionally, more incidence of grade 3 or 4 rash, fatigue and hypertension were observed in combining targeted therapy.
Conclusions: With the available evidence, combining targeted therapy seems superior over erlotinib monotherapy as second-line treatment for advanced NSCLC. More studies are still needed to identify patients who will most likely benefit from the appropriate combining targeted therapy.
推荐引用方式
GB/T 7714：

Qi Wei-Xiang,Wang Qiong,Jiang Yan-Ling, et al. Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data [J].PLOS ONE,2013,8(2).
APA：

Qi Wei-Xiang,Wang Qiong,Jiang Yan-Ling,Sun Yuan-Jue,&Yao Yang.(2013).Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data .PLOS ONE,8(2).
MLA：

Qi Wei-Xiang, et al. "Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data" .PLOS ONE 8,2(2013).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：67  下载次数：0

分享到：

浏览次数：67

下载次数：0

打印次数：0